Scarica l'app Stockscreener
104.89
0.20%
0.21
Pre-mercato:
104.62
-0.27
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$104.68
Aprire:
$105.65
Volume 24 ore:
8.24M
Relative Volume:
0.84
Capitalizzazione di mercato:
$181.50B
Reddito:
$46.59B
Utile/perdita netta:
$5.41B
Rapporto P/E:
33.90
EPS:
3.0938
Flusso di cassa netto:
$7.38B
1 W Prestazione:
+3.02%
1M Prestazione:
+2.22%
6M Prestazione:
+8.35%
1 anno Prestazione:
-18.40%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$100.63
$105.88
Portata 52W:
$81.97
$132.03
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-07 | Iniziato | Barclays | Overweight |
| 2026-10-02 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | Iniziato | Robert W. Baird | Outperform |
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
StoneX reiterates Buy on Abbott Labs stock ahead of earnings By Investing.com - Investing.com India
Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock - ad-hoc-news.de
TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H' - StreetInsider
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Pregnancy Tests Recalled Globally Over False Positives - Gizmodo
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Abbott Laboratories To Go Ex-Dividend On October 15th, 2026 With 0.63 USD Dividend Per Share - Moomoo
Abbott Laboratories stock may move 4.7% on earnings release - Investing.com
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins? - 24/7 Wall St.
SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock - Simply Wall Street
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - TradingView
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Abbott (ABT) Gains As Market Dips: What You Should Know - Zacks Investment Research
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals - ChartMill
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
Abbott Laboratories is More than a Dividend Stock. Here’s Why. - Yahoo Finance
What Is Abbott Laboratories (ABT) Telling Investors With Its New Product Push? - Simply Wall Street
Lake County-based Abbott to pay nearly $385 million over claims it made baby formula in leaky, unsanitary plant - Lake and McHenry County Scanner
Abbott Laboratories (ABT) Debuts Ensure Max Protein Powder With Creatine And HMB - Yahoo Finance
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. - The Motley Fool
Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure News - Yahoo Finance
Abbott Laboratories (ABT), Why Is Fresh Attention Building Around It? - Simply Wall Street
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff? - Yahoo Finance
Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything - https://www.lawnews.co.uk/
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
What Will the Libre Duo Launch Mean for Abbott Laboratories (NYSE:ABT)? - Kalkine Media
Abbott Laboratories stock: FDA approves new CardioMEMS capabilities - AD HOC NEWS
Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative? - Simply Wall Street
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield - 24/7 Wall St.
Abbott Laboratories stock trades 26.5 percent below its yearly high - AD HOC NEWS
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Redburn upgrades Abbott Laboratories stock to Buy - AD HOC NEWS
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Grace Groner bought three $60 shares of Abbott Laboratories in 1935 and worked there 43 years; she left more than $7 million to benefit Lake Forest College students when she died at 100 - Parade Magazine
AG Fitch announces $384M false claims settlement with Abbott Laboratories - Picayune Item
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Abbott Laboratories Azioni (ABT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
0.73%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):